• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?

作者信息

Ma Zhongren, Li Pengfei, Ikram Aqsa, Pan Qiuwei

机构信息

Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.

Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.

出版信息

Trends Immunol. 2020 Oct;41(10):851-853. doi: 10.1016/j.it.2020.08.002. Epub 2020 Aug 8.

DOI:10.1016/j.it.2020.08.002
PMID:32863136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7414423/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae35/7414423/50f681d5a2ab/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae35/7414423/50f681d5a2ab/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae35/7414423/50f681d5a2ab/gr1_lrg.jpg

相似文献

1
Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?新型冠状病毒的交叉中和作用仅与高致病性冠状病毒有关吗？
Trends Immunol. 2020 Oct;41(10):851-853. doi: 10.1016/j.it.2020.08.002. Epub 2020 Aug 8.
2
The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2.人致病性冠状病毒的出现：作为针对 SARS-CoV-2 的抗病毒药物的凝集素。
Curr Pharm Des. 2020;26(41):5286-5292. doi: 10.2174/1381612826666200821120409.
3
[The genome comparison of SARS-CoV and other coronaviruses].[严重急性呼吸综合征冠状病毒与其他冠状病毒的基因组比较]
Yi Chuan. 2003 Jul;25(4):373-82.
4
Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.SARS-CoV-2 和其他人类冠状病毒的致病性的基因组决定因素。
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15193-15199. doi: 10.1073/pnas.2008176117. Epub 2020 Jun 10.
5
Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.新型冠状病毒及其他人类冠状病毒致病性的基因组决定因素
bioRxiv. 2020 Apr 9:2020.04.05.026450. doi: 10.1101/2020.04.05.026450.
6
Properties of Coronavirus and SARS-CoV-2.冠状病毒及新型冠状病毒（SARS-CoV-2）的特性
Malays J Pathol. 2020 Apr;42(1):3-11.
7
G-Quadruplexes Are Present in Human Coronaviruses Including SARS-CoV-2.人冠状病毒包括新冠病毒中存在G-四链体。
Front Microbiol. 2020 Oct 23;11:567317. doi: 10.3389/fmicb.2020.567317. eCollection 2020.
8
Aerosol and surface persistence: Novel SARS-CoV-2 versus other coronaviruses.气溶胶和表面持久性：新型严重急性呼吸综合征冠状病毒2与其他冠状病毒的比较
J Infect Dev Ctries. 2020 Jul 31;14(7):748-749. doi: 10.3855/jidc.12887.
9
Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.Abbott ARCHITECT SARS-CoV-2 IgG 免疫分析与间接免疫荧光法和病毒微量中和试验的比较性能评估。
J Clin Virol. 2020 Aug;129:104539. doi: 10.1016/j.jcv.2020.104539. Epub 2020 Jul 6.
10
Comparative analysis of SARS-CoV-2 and its receptor ACE2 with evolutionarily related coronaviruses.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其受体血管紧张素转换酶2（ACE2）与进化相关冠状病毒的比较分析。
Aging (Albany NY). 2020 Nov 7;12(21):20938-20945. doi: 10.18632/aging.104024.

引用本文的文献

1
Accounting for Potential Unmeasured Confounding in the Association between Influenza vaccination and COVID-19 Hospitalization: Sensitivity Analysis Using E-value Method.流感疫苗接种与新冠病毒肺炎住院治疗之间关联中潜在未测量混杂因素的考量：使用E值法的敏感性分析
Tanaffos. 2022 Mar;21(3):330-335.
2
Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children.儿童对低致病性人类冠状病毒的预先存在的体液免疫对 SARS-CoV-2 表现出有限的交叉反应性抗体反应。
Front Immunol. 2022 Oct 19;13:1042406. doi: 10.3389/fimmu.2022.1042406. eCollection 2022.
3

本文引用的文献

1
Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context.在新冠疫情背景下估算低致病性人类冠状病毒的全球流行病学情况。
J Infect Dis. 2020 Jul 23;222(4):695-696. doi: 10.1093/infdis/jiaa321.
2
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
3
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
根据世界卫生组织国际结合抗体单位（BAU/mL），自然感染和随后接种疫苗后对 SARS-CoV-2 的长期体液免疫反应。
Viruses. 2021 Nov 23;13(12):2336. doi: 10.3390/v13122336.
4
Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.新型冠状病毒肺炎患者和历史样本中针对 SARS-CoV-2 蛋白 N、S 和 E 的抗体。
J Gen Virol. 2021 Nov;102(11). doi: 10.1099/jgv.0.001692.
5
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.SARS-CoV-2 抗体的综合概述及其在 COVID-19 预防和治疗中的可能应用。
Microb Cell Fact. 2021 Apr 22;20(1):88. doi: 10.1186/s12934-021-01576-5.
6
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.针对人冠状病毒 OC43 刺突蛋白的交叉反应性抗体与 COVID-19 患者的疾病严重程度相关：一项回顾性研究。
Emerg Microbes Infect. 2021 Dec;10(1):664-676. doi: 10.1080/22221751.2021.1905488.
7
HLA, Immune Response, and Susceptibility to COVID-19.人类白细胞抗原、免疫反应与 COVID-19 易感性。
Front Immunol. 2021 Jan 8;11:601886. doi: 10.3389/fimmu.2020.601886. eCollection 2020.
8
Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2.低致病性人类冠状病毒特异性抗体对严重急性呼吸综合征冠状病毒2的影响。
Trends Immunol. 2020 Oct;41(10):853-854. doi: 10.1016/j.it.2020.08.003. Epub 2020 Aug 11.
新冠病毒和非典病毒感染之间的交叉反应性抗体反应。
Cell Rep. 2020 Jun 2;31(9):107725. doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
4
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.高通量单细胞测序鉴定恢复期患者 B 细胞中的 SARS-CoV-2 强效中和抗体。
Cell. 2020 Jul 9;182(1):73-84.e16. doi: 10.1016/j.cell.2020.05.025. Epub 2020 May 18.
5
Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.2020 年 4 月 10 日至 11 日，加利福尼亚州洛杉矶县成年人中 SARS-CoV-2 特异性抗体的血清流行率。
JAMA. 2020 Jun 16;323(23):2425-2427. doi: 10.1001/jama.2020.8279.
6
Commentary: SARS, MERS and COVID-19-new threats; old lessons.评论：严重急性呼吸综合征、中东呼吸综合征和2019冠状病毒病——新威胁；旧教训
Int J Epidemiol. 2020 Jun 1;49(3):726-728. doi: 10.1093/ije/dyaa061.
7
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.常规静脉注射免疫球蛋白治疗对新型冠状病毒肺炎（COVID-19）重症肺炎患者预后的影响。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
8
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
9
Zoonotic origins of human coronaviruses.人畜共患起源的人类冠状病毒。
Int J Biol Sci. 2020 Mar 15;16(10):1686-1697. doi: 10.7150/ijbs.45472. eCollection 2020.
10
Potential association between COVID-19 mortality and health-care resource availability.新型冠状病毒肺炎死亡率与医疗资源可及性之间的潜在关联。
Lancet Glob Health. 2020 Apr;8(4):e480. doi: 10.1016/S2214-109X(20)30068-1. Epub 2020 Feb 25.